These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25071012)

  • 1. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
    Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
    Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models.
    Park JH; Kim MJ; Kim WJ; Kwon KD; Ha KT; Choi BT; Lee SY; Shin HK
    Cancer Lett; 2020 May; 478():71-81. PubMed ID: 32173479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
    Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
    Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.
    Kwiatkowski SC; Guerrero PA; Hirota S; Chen Z; Morales JE; Aghi M; McCarty JH
    PLoS One; 2017; 12(9):e0185065. PubMed ID: 28938007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
    Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
    Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
    Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
    Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.
    Deng L; Stafford JH; Liu SC; Chernikova SB; Merchant M; Recht L; Martin Brown J
    Neoplasia; 2017 Jan; 19(1):1-7. PubMed ID: 27940247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
    Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
    Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.
    Abdul Rahim SA; Dirkse A; Oudin A; Schuster A; Bohler J; Barthelemy V; Muller A; Vallar L; Janji B; Golebiewska A; Niclou SP
    Br J Cancer; 2017 Sep; 117(6):813-825. PubMed ID: 28797031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspective: targeting VEGF-A and YKL-40 in glioblastoma - matter matters.
    Holst CB; Pedersen H; Obara EAA; Vitting-Seerup K; Jensen KE; Skjøth-Rasmussen J; Lund EL; Poulsen HS; Johansen JS; Hamerlik P
    Cell Cycle; 2021 Apr; 20(7):702-715. PubMed ID: 33779510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.
    Scholz A; Harter PN; Cremer S; Yalcin BH; Gurnik S; Yamaji M; Di Tacchio M; Sommer K; Baumgarten P; Bähr O; Steinbach JP; Trojan J; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Braun C; Schittenhelm J; Frueh JT; Ullrich E; Mittelbronn M; Plate KH; Reiss Y
    EMBO Mol Med; 2016 Jan; 8(1):39-57. PubMed ID: 26666269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
    Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
    Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
    Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
    Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
    [No Abstract]   [Full Text] [Related]  

  • 18. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
    Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
    Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy.
    Liang J; Piao Y; Henry V; Tiao N; de Groot JF
    Oncotarget; 2015 Oct; 6(31):31479-92. PubMed ID: 26362401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.